ClinicalTrials.gg
CompletedNCT02226978Updated Aug 27, 2014

Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

A Phase 1 interventional study of Tipranavir and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Ages
20 Years to 58 Years
Sex
All
01

Study summary

Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a prodrug of aciclovir (ACV)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and non-pregnant, non-lactating female subjects as determined by results of screening
  • Signed written in accordance with Good Clinical Practice (GCP) and local legislation
  • The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and willingness to comply with all study requirements
  • Age >19 and \<59 years (20 - 58 years inclusive)
  • Weight ≥ 60 kg
  • (BMI) >18.5 and \<29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate, and ) deviating from normal and of clinical relevance
  • Atrioventricular (AV) block including 1°
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, oncological or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Relevant history of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Known hypersensitivity to TPV, RTV, valaciclovir, aciclovir or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
  • Known elevated liver enzymes in past trials with any compound
  • Intake of drugs with a long half-life (>24 hours) (\<1 month prior to administration)
  • Prescription or over the counter medications (including vitamins, minerals, herbal supplements and antacids), dietary supplements 14 days prior to study drug administration or expected during the trial)
  • Participation in another trial with an drug (\<2 months prior to administration or expected during trial)
  • Smoker with a consumption of >10 cigarettes or >3 cigars or >3 pipes/day and those who cannot keep tobacco intake constant
  • Alcohol (>40 g/day for males and >20 g/day for females) and drug abuse
  • Blood donation or loss >400 mL, \< 3 month prior to administration
  • laboratory abnormalities
  • Transaminases above reference values in the history
  • Inability to comply with dietary regimen of study centre

For female subjects:

  • Pregnancy or planning to become pregnant within 60 days of study completion
  • Positive pregnancy test
  • Have not been using a barrier method of for at least 3 months prior to participation in the study if of and not surgically sterilized
  • Are not willing or are unable to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and up to 2 months after completion/termination of the trial if of childbearing potential and not surgically sterilized
  • Chronic use of oral contraception or hormone replacement containing ethinyl estradiol
  • Breast-feeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    TPV/r with valaciclovir

    VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)

    Drug: Tipranavir · Drug: Ritonavir · Drug: Valaciclovir

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of aciclovir in plasma over the time interval t0h to t12h (AUC0-12)

    Time frame: up to 12 hours after drug administration

  2. Maximum measured concentration of aciclovir in plasma (Cmax)

    Time frame: up to 12 hours after drug administration

Secondary outcomes

  1. AUC0-12 for Tipranavir (TPV)

    Time frame: up to 12 hours after drug administration

  2. Cmax for TPV

    Time frame: up to 12 hours after drug administration

  3. Drug concentration of TPV in plasma at 12 hours after administration (C12h)

    Time frame: up to 12 hours after drug administration

  4. Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)

    Time frame: up to 12 hours after drug administration

  5. Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)

    Time frame: up to 12 hours after drug administration

  6. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: up to 12 hours after drug administration

  7. Number of subjects with adverse events

    Time frame: up to 14 days after last drug administration

  8. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 14 days after last drug administration

  9. AUC0-12 for Ritonavir (RTV)

    Time frame: up to 12 hours after drug administration

  10. Cmax for RTV

    Time frame: up to 12 hours after drug administration

  11. Drug concentration of RTV in plasma at 12 hours after administration (C12h)

    Time frame: up to 12 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007 and a primary completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2014
First posted
Aug 27, 2014
Start
Feb 2007
Primary completionActual
May 2007
Last update
Aug 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02226978
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Feb 2007
Primary completion
May 2007
Last update
Aug 27, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Valacyclovir

Start the discussion